Cipla Share Price
₹1,499.75 -5.85 (-0.39%)
16 Nov, 2024 13:07
Start SIP in
CIPLA
Performance
- Low
- ₹1,490
- High
- ₹1,517
- 52 Week Low
- ₹1,165
- 52 Week High
- ₹1,702
- Open Price₹1,497
- Previous Close₹1,506
- Volume1,469,143
Investment Returns
- Over 1 Month -4.58%
- Over 3 Month -4.1%
- Over 6 Month + 6.61%
- Over 1 Year + 20.78%
Smart Investing Starts Here Start SIP with Cipla for Steady Growth!
Cipla Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 27.1
- PEG Ratio
- 0.9
- Market Cap Cr
- 121,119
- P/B Ratio
- 4.5
- Average True Range
- 40.85
- EPS
- 57.16
- Dividend Yield
- 0.9
- MACD Signal
- -13.06
- RSI
- 41.01
- MFI
- 58.76
Cipla Financials
Cipla Technicals
EMA & SMA
-
- Bullish Moving Average 1
-
- Bearish Moving Average 15
- 20 Day
- ₹1,546.88
- 50 Day
- ₹1,565.77
- 100 Day
- ₹1,553.50
- 200 Day
- ₹1,489.90
Resistance and Support
- R3 1,541.17
- R2 1,529.08
- R1 1,514.42
- S1 1,487.67
- S2 1,475.58
- S3 1,460.92
Cipla Corporate Actions - Bonus, Splits, Dividends
Cipla F&O
About Cipla
Cipla Ltd. is a pharmaceutical company in India with a strong global presence. With operations in 80 countries and 47 manufacturing facilities, it sells 1500 products in the market. The largest market of Cipla Ltd. is India, followed by Africa and North America.
The product profile of Cipla Ltd. ranges from drugs in the respiratory, pediatric asthma, nebulisation, anti-retroviral, urology, cardiology, anti-infective, CNS, and several other illnesses and disorders. Cipla's business is divided into three units - Generics and Branded Generics, Specialty and Consumer Health.
The Generics and Branded Generics unit contributes around 19% of the pharmaceutical revenues in India. The division has 4,000+ partners covering the entire country and is constantly seeking to expand the product portfolio.
The Specialty unit focuses on speciality medicines in respiratory, CNS and critical care. This unit's operations are run under Cipla Technologies LLC (CipTec) and have its headquarters in San Diego, California.
The Consumer Health Segment focuses on simplifying healthcare and offering simple and over-the-counter solutions to the consumers. A few brands under this business unit are Nicotex, ActivKids ImmunoBoosters, Cofsils, and UnoBiotics.
Cipla was founded in 1935 in Mumbai as Chemical Industrial & Pharmaceutical Laboratories Ltd. by Khwaja Abdul Hamied. The name of the company was changed to Cipla in 1984. It received a major boost in 1985 when the US FDA approved its bulk drug facility. Cipla went on to launch the world's first oral iron chelator in 1995.
The company acquired the South African company Cipla-Medproin in 2013 and entered digital therapeutics by partnering with Wellthy Therapeutics in India and Brandmed in South Africa in 2019.
In September 2021, Cipla Ltd. subscribed to 5% equity shares (on a fully diluted basis) of Swasth Digital Health Foundation. It is a not-for-profit organisation focused on building digital healthcare infrastructure.
Shareholding Pattern
A total of 230 mutual funds invest in Cipla Ltd., with a total holding of 13.91%. The number of FIIs and FPIs that have invested in it is 786, and their total holding amount to 26.64. These figures are as of March 2022.
The top mutual funds that have invested in Cipla Ltd. are SBI ETF Nifty 50, Baroda BNP Paribas Balanced Advantage Fund Regular Growth, Mirae Asset Healthcare Fund Regular Growth, Franklin India Bluechip Fund-Growth and UTI Nifty ETF.
View More- NSE Symbol
- CIPLA
- BSE Symbol
- 500087
- Managing Director & Global CEO
- Mr. Umang Vohra
- ISIN
- INE059A01026
Similar Stocks to Cipla
Cipla FAQs
Cipla share price is ₹1,499 As on 16 November, 2024 | 12:53
The Market Cap of Cipla is ₹121119.1 Cr As on 16 November, 2024 | 12:53
The P/E ratio of Cipla is 27.1 As on 16 November, 2024 | 12:53
The PB ratio of Cipla is 4.5 As on 16 November, 2024 | 12:53
Cipla may be the correct pick right now for investors searching for value buys of quality stocks with a longer time horizon. Cipla comes with a HOLD recommendation from the analyst. Cipla has a trailing 12-month operating revenue of INR 20,799.29 crore. Annual revenue growth of 11% is strong, the pre-tax margin of 17% is excellent, and ROE of 13% is excellent. The company has a debt-to-equity ratio of 7%, which indicates a stable balance sheet. Institutional holding has gone up in the last reported quarter is a positive sign.
Cipla Limited, headquartered in Mumbai, India, is an Indian multinational pharmaceutical corporation. Cipla primarily produces drugs for the treatment of respiratory, cardiovascular, arthritis, diabetes, weight loss, and depression, as well as other medical disorders.
Umang Vohra has been the CEO of Cipla since 1 September 2016.
Cipla's stock price CAGR over ten years is 11%, five years is 10%, three years is 20%, and one year is 22% percent.
You can easily buy the shares of Grasim Industries Ltd. by registering at 5Paisa and setting up a Demat Account in your name to start trading.
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.